申请人:ALTERITY THERAPEUTICS LIMITED
公开号:US11357770B2
公开(公告)日:2022-06-14
The present invention relates to the use of substituted quinoline compounds for treating immunoglobulin light chain (LC) amyloidosis (AL), especially cardiotoxicity associated with immunoglobulin LC AL. In particular, the substituted quinoline compounds useful in the treatment of cardiac LC amyloidosis are 5,7-dihalo-8-hydroxyquinoline derivatives, especially 5,7-dichloro-8-hydroxyquinoline derivatives.
本发明涉及使用取代的喹啉化合物治疗免疫球蛋白轻链(LC)淀粉样变性(AL),特别是与免疫球蛋白LC AL相关的心脏毒性。特别是,用于治疗心脏LC淀粉样变性的取代喹啉化合物是5,7-二卤-8-羟基喹啉衍生物,尤其是5,7-二氯-8-羟基喹啉衍生物。